Iclusig

Approved Uses

Iclusig is primarily used to treat adults with the following conditions:

• Chronic Myeloid Leukemia (CML): This includes the chronic phase, accelerated phase, and blast phase. It is typically used when other treatments have not worked or are not suitable for the patient.
• Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): It is used for patients who cannot tolerate other therapies or who have specific genetic markers that make other treatments less effective.
• T315I Mutation: Iclusig is specifically indicated for patients with CML or Ph+ ALL who have a genetic mutation known as T315I. This mutation often makes the cancer resistant to other similar medications.

Recent Approvals

Iclusig may also be used in combination with chemotherapy for adults who have been newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Treatment Considerations

Because of the potential for serious side effects, healthcare providers usually prescribe Iclusig only when other tyrosine kinase inhibitor (TKI) therapies are no longer effective or cannot be used. It is intended for patients for whom no other treatment is indicated or those with the specific T315I mutation.

How Iclusig Works

Iclusig is a type of targeted therapy known as a tyrosine kinase inhibitor (TKI). It works by interfering with the specific proteins that tell cancer cells to grow and divide.

In certain types of leukemia, such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), a genetic abnormality creates a protein called BCR-ABL. This protein acts like a switch that is permanently stuck in the "on" position, causing the bone marrow to produce too many abnormal white blood cells.

Iclusig works through the following actions:

• Blocking Growth Signals: The medication binds to the BCR-ABL protein, preventing it from sending the signals that cause cancer cells to multiply.
• Targeting Mutations: Some leukemia cells develop mutations, such as the T315I mutation, which change the shape of the BCR-ABL protein. While many other drugs cannot bind to this altered protein, Iclusig is designed to fit into the protein even when this mutation is present.
• Slowing Disease Progression: By inhibiting these proteins, Iclusig helps to reduce the number of cancerous cells and allows the body to produce healthier blood cells.

Common Side Effects

Many people taking Iclusig experience side effects during treatment. Some of the most frequently reported include:

• Skin rash, dry skin, or itching
• Stomach pain, nausea, or vomiting
• Constipation or diarrhea
• Fatigue and general weakness
• Headache
• Joint, muscle, or bone pain
• Fever
• Cough or shortness of breath
• Swelling in the arms, legs, or feet

Serious Side Effects

Iclusig can cause severe complications that require immediate medical intervention. These may include:

• Vascular problems: Serious blood clots in the arteries or veins, which may lead to heart attack, stroke, or loss of blood flow to the limbs.
• Heart failure: Symptoms include shortness of breath, swelling, or rapid weight gain.
• Liver damage: Signs include yellowing of the skin or eyes, dark urine, and pain in the upper right side of the stomach.
• Pancreatitis: Inflammation of the pancreas causing severe stomach pain that radiates to the back.
• Severe hypertension: A sudden or significant increase in blood pressure.
• Vision issues: Blurred vision, eye pain, or sudden vision loss.
• Hemorrhage: Serious internal or external bleeding.
• Low blood cell counts: Reduced levels of platelets, red blood cells, or white blood cells, which can increase the risk of bleeding, anemia, or infection.
• Neurological issues: Confusion, seizures, or severe headaches associated with posterior reversible encephalopathy syndrome (PRES).

Boxed Warnings

Iclusig carries boxed warnings for several serious and potentially life-threatening conditions:

• Arterial Occlusive Events: Serious blood clots have occurred in the arteries, leading to heart attacks, strokes, and severe narrowing of blood vessels in the limbs. These events have occurred in patients with and without cardiovascular risk factors and may require urgent medical intervention or lead to death.
• Venous Thromboembolism: Blood clots in the veins, including deep vein thrombosis and pulmonary embolism, have been reported.
• Heart Failure: This medication can cause new or worsening heart failure, which may be fatal. Heart function is typically monitored closely during treatment.
• Hepatotoxicity: Severe liver damage, liver failure, and death have occurred. Liver function tests are generally performed before starting treatment and monitored regularly thereafter.

Other Serious Precautions

Hypertension

High blood pressure is a common side effect and can become severe. In some cases, it may lead to a hypertensive crisis. Blood pressure should be monitored at every clinic visit, and treatment may be interrupted or the dose reduced if hypertension is not controlled.

Pancreatitis

Inflammation of the pancreas (pancreatitis) has been reported. Healthcare providers usually monitor serum lipase levels frequently, especially during the first few months of therapy.

Hemorrhage

Serious bleeding events, including gastrointestinal bleeding and brain bleeds, have occurred. Some of these events have been fatal. Patients should be monitored for signs of unusual bleeding or bruising.

Fluid Retention

Iclusig can cause the body to retain fluid, which may lead to swelling in the extremities or fluid accumulation around the heart or lungs.

Cardiac Arrhythmias

Irregular heartbeats, such as atrial fibrillation or a slow heart rate (bradycardia), have been observed in patients taking this medication.

Gastrointestinal Perforation

Holes in the wall of the stomach or intestines (perforation) have occurred. Patients should be monitored for symptoms such as severe abdominal pain, nausea, or vomiting.

Wound Healing and Surgery

This medication may impair the body's ability to heal wounds. It is typically recommended to stop taking the drug for at least one week before elective surgery and to wait at least two weeks after surgery before resuming.

Embryo-Fetal Toxicity

Iclusig can cause harm to a developing fetus if taken during pregnancy. Individuals of reproductive potential are advised to use effective contraception during treatment and for three weeks after the final dose.

Pregnancy

Iclusig may cause fetal harm or birth defects if taken during pregnancy. Healthcare providers typically require a pregnancy test before starting treatment for individuals of reproductive potential. It is important to use effective birth control during treatment and for at least 3 weeks after the final dose. If pregnancy occurs while taking this medication, a healthcare professional should be contacted immediately to discuss the potential risks to the fetus.

Breastfeeding

It is not known whether Iclusig passes into human breast milk. Because of the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment and for at least 6 days after the last dose.

Fertility

Based on animal studies, Iclusig may impair fertility in females. The long-term effects on human fertility are not fully known. Individuals concerned about their ability to have children should discuss these risks with their healthcare provider before beginning treatment.

Available Forms

Iclusig is available as a film-coated tablet for oral use. It is not available in other forms such as liquids or injections.

• Oral Tablet

Patients are advised to swallow the tablets whole. The medication should not be crushed, broken, or chewed before swallowing.

FDA Approval History

Iclusig was first approved by the FDA in December 2012. It is indicated for adults with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to previous kinase inhibitor therapies, or who have the T315I mutation.

In March 2024, the FDA granted accelerated approval for Iclusig to be used in combination with chemotherapy for adults with newly diagnosed Ph+ ALL. Continued approval for this specific use may depend on verification of clinical benefit in confirmatory trials.

Safety Communications and Restrictions

In 2013, the FDA issued a safety communication and briefly suspended the marketing of Iclusig due to an increased frequency of reports involving life-threatening blood clots and severe narrowing of blood vessels. The drug was later allowed back on the market with additional safety measures, including a revised label and a Risk Evaluation and Mitigation Strategy (REMS).

Boxed Warning

The FDA requires a Boxed Warning for Iclusig, which is the most serious type of warning. This warning covers several critical risks:

• Arterial Occlusive Events: Serious and sometimes fatal blood clots in the arteries, which can lead to heart attack, stroke, or decreased blood flow to the limbs.
• Venous Thromboembolism: Blood clots in the veins, such as deep vein thrombosis or pulmonary embolism.
• Heart Failure: The drug may cause the heart muscle to weaken or fail.
• Hepatotoxicity: Potential for severe liver damage, liver failure, or death.

Because of these risks, the FDA requires the Iclusig REMS program to ensure that healthcare providers are informed about the risks and that the drug is used only in patients for whom the benefits outweigh these serious safety concerns.

Insurance and Prior Authorization

Most insurance plans may cover Iclusig, but it is often classified as a specialty drug. This classification usually requires a process called prior authorization, where a healthcare provider must submit documentation to the insurance company to confirm the medication is medically necessary before coverage is approved.

Specialty Pharmacies

Iclusig is not available at most standard retail pharmacies. It must be obtained through a specialty pharmacy that is authorized to dispense this type of medication. These pharmacies often provide additional services, such as coordinating delivery and helping patients navigate insurance requirements.

Financial Assistance Programs

Because of the high cost of treatment, the manufacturer and various non-profit organizations may offer financial assistance programs. These options may include:

• Co-pay cards for patients with commercial insurance
• Patient assistance programs for those who are uninsured or underinsured

Patients are encouraged to discuss these options with their doctor or a hospital social worker.